ASCO: Clovis stock doubles on possible ''breakthrough'' lung cancer drug
This article was originally published in Scrip
Executive Summary
Investors doubled the value of Clovis Oncology on 3 June to close up 103.9% at $74.59 per share based on positive Phase I data from six lung cancer patients treated with the Boulder, Colorado-based company's EGFR inhibitor CO-1686, which may be a candidate for the US FDA's breakthrough therapy designation.